High-quality Algerian insulin at local prices starting from 2016

The Vice President General Manager, in charge of pharmaceutical laboratories “Novo Nordisk” for the Africa region, John Paul Digui, has announced the official marketing launch of an high-grade Algerian-made “insulin" starting from 2016, and at lower prices than those currently in force, given that the manufacture of this pharmaceutical product will be carried out be locally.
Mr Digui told “Echorouk” on the sidelines of the international forum of francophone countries on diabetes held in the city of Bordeaux in France, that Denmark’s “Novo Nordisk” in partnership with Algerian "Saidal" firm had transferred all modern technologies to manufacture this anti-diabetes drug by guaranteeing the same level of quality that is found in Denmark, and in seven other advanced world countries
He also indicated that the relevant factory located in the province of Tizi Ouzou east of Algiers is set to produce more anti-diabetes pills "Metformine" by doubling its potential late last year, and will produce the "Robaklinid" pills shortly as part of this mutually-profitable partnership venture.
The Oued Aissi Plant (Tizi Ouzou), coming under Novo Nordisk laboratories will start production of new drug for diabetes patients in 2015, confirmed for his part the new CEO of Novo Nordisk Algeria, Peter Ulvskjold.
The Oued Aissi plant which produces “Metformine” as part of the Algerian-Danish Partnership will start soon the production of “NovoNorm”, Mr Ulvskjold told local media outlets.
Created in 2006, this plant is fully managed by Algerian skills and is being currently equipped for the manufacturing of “NovoNorm” next year, he said, calling the manufacturing of this new drug a "new milestone" in the partnership between Algeria and the Danish laboratories “Novo Nordisk”. 
Now, the plant produces 30 million boxes of “Metformine”, he asserted. After meeting the needs of the national market, the plant "will export to African countries," the same official added.
Concerning the partnership with Saidal firm for the manufacturing of insulin, Mr Ulvskjold announced that it will be produced in the Constantine-based  Plant and will be marketed locally next year.
In the beginning, the plant will produce 10% of classic insulin, before producing modern insulin as from 2016.
Regarding the partnership with the Ministry of Health, Population and Hospital Reform, the official pointed to the project of a mobile clinic that traveled since its launch in 2011 in several provinces of the country. It aims to provide early diagnosis of diabetes and awareness.
Mr Ulvskjold also expressed his company’s willingness to continue fulfilling the fruitful health-related projects agreed upon with the Algerian government.